Prostate-specific targeting using PSA promoter-based lentiviral vectors

Cancer Gene Therapy

Volumn 8, Issue 9, 2001, Pages 628-635

  Yu, Duan ^a   Chen, Dalin ^a   Chiu, Chris ^a   Razmazma, Babak ^a   Chow, Yen Hung ^a   Pang, Shen ^a  

^a UCLA SCHOOL OF DENTISTRY   (United States)

Author keywords

DTA; Prostate cancer; PSA; PSA promoter; Tissue specific

Indexed keywords

GREEN FLUORESCENT PROTEIN; PROSTATE SPECIFIC ANTIGEN; VIRUS VECTOR;

ANTIGEN SPECIFICITY; ARTICLE; DNA FLANKING REGION; EPITHELIUM CELL; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRINAE; MOLECULAR CLONING; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; TUMOR GROWTH; VIRUS PARTICLE;

ANIMALS; COLLAGEN; DIPHTHERIA TOXIN; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; INJECTIONS, SUBCUTANEOUS; LAMININ; LUMINESCENT PROTEINS; MALE; MICE; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; PROMOTER REGIONS (GENETICS); PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEOGLYCANS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034804819     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700344     Document Type: Article

References (39)

1. Neoadjuvant hormonal therapy in the management of prostate cancer: A surgical and radiation therapy review
2. Current treatment of advanced prostate cancer
3. Treatment of hormone-refractory prostate carcinoma
4. Hormone therapy for patients with prostate carcinoma
5. Management of hormone refractory prostate cancer: Current standards and future prospects
6. Prostate antigen: A new potential marker for prostatic cancer
7. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: I. Untreated patients
8. Screening for carcinoma of the prostate with prostate specific antigen
9. Urinary prostate specific antigen levels: Role in monitoring the response of prostate cancer to therapy
10. Hormone therapy prior to radical prostatectomy in patients with clinical stage C prostate cancer
11. Relationship between changes in prostate-specific antigen and prognosis of prostate cancer
12. Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy
13. High dose epirubicin is effective in measurable metastatic prostate cancer: A phase II study of the EORTC Genitourinary Group
14. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element
15. Prostate-specific antigen expression is regulated by an upstream enhancer
16. High throughput analysis of differential gene expression
17. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer
18. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen
19. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines
20. Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene
21. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
22. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector
23. Transcriptionally regulated adenoviruses for prostate-specific gene therapy
24. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
25. Inactivation of the p53 gene by either mutation or HPV infection is extremely frequent in human oral squamous cell carcinoma cell lines
26. Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells
27. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector
28. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons
29. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP
30. Identification of two novel cis-elements in the promoter of the prostate-specific antigen gene that are required to enhance androgen receptor-mediated transactivation
31. Relative activity and specificity of promoters from prostate-expressed genes
32. Progress in transcriptionally targeted and regulatable vectors for genetic therapy
33. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors
34. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
35. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal
36. Construction of adenovirus vectors through Cre-lox recombination
37. Lentiviral vectors for the genetic modification of hematopoietic stem cells
38. Lentiviral vectors
39. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer